The Epidemiology of COVID-19 and MS-Related Characteristics in a National Sample of People With MS in China

Zhang, Yao; Yin, Hexiang; Xu, Yuanfu; Xu, Tao; Peng, Bin; Zhang, Shuyang

doi:10.3389/fneur.2021.682729

Cited by 7 publications

(6 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A large cohort from China suggested that relapse rates were determined mainly by MS itself and compliance to medications and not the pandemic ( Jj et al, 2020 ). Similarly, a study by Zhang reported increased MS relapses during the pandemic mostly in patients with poor compliance to DMT ( Zhang et al, 2021 ). Our study demonstrated a reduction in MS disease activities of up to 70 % during the pandemic, compared to the three years preceding the pandemic.…”

Section: Discussionmentioning

confidence: 84%

The disease course of multiple sclerosis before and during COVID-19 pandemic: A retrospective five-year study

Babtain

Bajafar

Nazmi

et al. 2022

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 84%

The disease course of multiple sclerosis before and during COVID-19 pandemic: A retrospective five-year study

Babtain

Bajafar

Nazmi

et al. 2022

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

“…Since Multiple Sclerosis especially affects active, young adults and the treatment options include immunosuppressive drugs, developments related to COVID-19 are followed with curiosity and meticulousness by neurologists. Increasing number of studies had showed that the course of the COVID-19 disease in pwMS is similar to normal population with similar age and comorbidities, and there is no increase in the risk of developing the disease with effective preventive approaches 8,9 .…”

Section: Discussionmentioning

confidence: 99%

Does pandemic change the ocrelizumab therapy approach? Yes. : Single center ocrelizumab experience

Tezer¹,

Doğan²,

Atmaca³

et al. 2022

Ideggyógyászati szemle

View full text Add to dashboard Cite

We know that treatment algorithms have changed in Multiple Sclerosis (MS) practice during the pandemic. In this study, we aimed to investigate whether there was a change in the patient population for ocrelizumab (OCR) treatment during the pandemic period, the treatment compliance of the patients, and the course of the Coronavirus Disease-19 (COVID-19) disease in the patients who received OCR. Our study was designed as a survey study. A questionnaire was sent to the patients assessing whether they had COVID-19 infection, whether they received treatments regularly before and after the pandemic, vaccination status and duration of OCR treatment. Demographic characteristics of the patients, treatments they used before, MS type, Expanded Disability Status Scale (EDSS) scores were determined from the database. Each group of OCR started before pandemic and OCR started after pandemic were compared. We included into the study 86 patients who started OCR before pandemic period and 75 patients who started OCR after the pandemic. Demographic features were similar. EDSS scores were higher in the group that started OCR treatment before the pandemic (p<0.0001). The patients who started OCR treatment before the pandemic had more disruptions than which started during the pandemic (p<0.0001). No correlation was found between the duration of OCR treatment and COVID-19 infection (p=0.940). We observed that the patients who had severe COVID-19 infection had received OCR therapy for a longer period. This retrospective study concluded that the OCR treatment approach in our center had changed during the pandemic period. OCR therapy was started in patients with less disability. The possible reasons for this situation include the proven relationship between high EDSS and serious COVID-19 infection, and that the patients who have higher EDSS score had troubles in reaching health institutions during the pandemic. The result that patients with severe COVID-19 infection received OCR treatment for a longer period necessitates more evidence-based research to investigate the relationship between treatment duration and disease severity.

show abstract

“…An important insight into relapse risk was presented in a study of Chinese pwMS, where a significant increase in relapse rate during the pandemic was observed, but only in those patients who experienced treatment discontinuation, dose reduction, or were not receiving any MS therapy [41].…”

Section: Recovery From Covid-19 In Ms Patientsmentioning

confidence: 99%

Navigating the landscape of COVID-19 for Multiple Sclerosis patients and clinicians

Dyczkowska

Kalinowska-Łyszczarz

2023

Neurol Neurochir Pol.

View full text Add to dashboard Cite

The purpose of this literature review was to summarise relevant findings regarding the clinical management of multiple sclerosis (MS) in the COVID-19 pandemic, with the focus on patient risks, and the implications of disease-modifying treatment, both on COVID-19 severity and on the response to the SARS-CoV-2 vaccinations. Although MS per se does not seem to put patients at risk for more severe COVID-19, alongside the risk factors known to apply to the general population, progressive disease course, higher disability status, and B-cell depleting therapies may all negatively affect infection severity. The question of COVID-19 sequelae in patients with MS (pwMS) remains unresolved, challenging researchers to further explore this area. The safety profile of COVID-19 vaccinations in pwMS is similar to that of the general population. The efficacy of the vaccination might be affected by B-cell depletion, as well as by S1PR-modulating medications that attenuate humoral responses to the COVID-19 vaccination. Future research should focus on gathering evidence regarding the clinical course of MS following COVID-19 infection and vaccination in larger studies, as well as on establishing the safest and most efficient schedule of COVID-19 vaccination in pwMS on cell-depleting therapies.

show abstract

The Epidemiology of COVID-19 and MS-Related Characteristics in a National Sample of People With MS in China

Cited by 7 publications

References 29 publications

The disease course of multiple sclerosis before and during COVID-19 pandemic: A retrospective five-year study

The disease course of multiple sclerosis before and during COVID-19 pandemic: A retrospective five-year study

Does pandemic change the ocrelizumab therapy approach? Yes. : Single center ocrelizumab experience

Navigating the landscape of COVID-19 for Multiple Sclerosis patients and clinicians

Contact Info

Product

Resources

About